BR112018076684A2 - anticorpos pd-l1 específicos e métodos de uso dos mesmos - Google Patents

anticorpos pd-l1 específicos e métodos de uso dos mesmos

Info

Publication number
BR112018076684A2
BR112018076684A2 BR112018076684-4A BR112018076684A BR112018076684A2 BR 112018076684 A2 BR112018076684 A2 BR 112018076684A2 BR 112018076684 A BR112018076684 A BR 112018076684A BR 112018076684 A2 BR112018076684 A2 BR 112018076684A2
Authority
BR
Brazil
Prior art keywords
antibodies
fragments
present disclosure
bind
methods
Prior art date
Application number
BR112018076684-4A
Other languages
English (en)
Inventor
Belk Jonathan
J. Sharkey Nathan
Gorelik Leonid
Original Assignee
Checkpoint Therapeutics, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Checkpoint Therapeutics, Inc filed Critical Checkpoint Therapeutics, Inc
Publication of BR112018076684A2 publication Critical patent/BR112018076684A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente divulgação se refere, em geral, a anticorpos e fragmentos funcionais ligantes dos mesmos que se ligam ao ligante de morte programada 1 (pd-l1). em particular, os anticorpos e fragmentos descritos se ligam à pd-l1 humana e compreendem novas regiões de determinação complementares (cdrs) também aqui descritas. por fim, a presente divulgação se refere a administração doas anticorpos e fragmentos descritos a indivíduos com câncer, assim, tratando ou diminuindo a progressão ou proliferação do câncer.
BR112018076684-4A 2016-06-29 2017-06-28 anticorpos pd-l1 específicos e métodos de uso dos mesmos BR112018076684A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356105P 2016-06-29 2016-06-29
US62/356,105 2016-06-29
PCT/US2017/039810 WO2018005682A2 (en) 2016-06-29 2017-06-28 Pd-l1-specific antibodies and methods of using the same

Publications (1)

Publication Number Publication Date
BR112018076684A2 true BR112018076684A2 (pt) 2019-04-02

Family

ID=60785529

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076684-4A BR112018076684A2 (pt) 2016-06-29 2017-06-28 anticorpos pd-l1 específicos e métodos de uso dos mesmos

Country Status (13)

Country Link
US (3) US10590199B2 (pt)
EP (1) EP3478723A4 (pt)
JP (2) JP7148414B2 (pt)
KR (2) KR102422411B1 (pt)
CN (1) CN109641960A (pt)
AU (1) AU2017290709B2 (pt)
BR (1) BR112018076684A2 (pt)
CA (1) CA3027204A1 (pt)
IL (2) IL263611B (pt)
MX (1) MX2018016183A (pt)
RU (1) RU2749109C2 (pt)
SG (2) SG11201810927QA (pt)
WO (1) WO2018005682A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN109641960A (zh) * 2016-06-29 2019-04-16 检查点治疗公司 Pd-l1特异性抗体及使用其的方法
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
JP7092404B2 (ja) * 2018-10-31 2022-06-28 イミュニティーバイオ、インコーポレイテッド Ｐｄ－ｌ１キメラ抗原受容体を発現するｎｋ細胞によるｐｄ－ｌ１陽性悪性腫瘍の排除
KR102207478B1 (ko) * 2019-03-13 2021-01-26 한국도로공사 시간 정보를 활용한 톨링 시스템 및 그의 구동 방법
AU2020261961B2 (en) * 2019-04-26 2022-07-07 I-Mab Biopharma Co., Ltd. Human PD-L1 antibodies
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CN113121686A (zh) * 2019-12-31 2021-07-16 迈威(上海)生物科技股份有限公司 抗pd-l1抗体及其应用
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN103146708A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
KR101888321B1 (ko) * 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CA2627890A1 (en) 2005-10-31 2007-05-10 The Government Of The United States As Represented By The Secretary Of H Ealth And Human Services, National Institutes Of Health Antibodies and immunotoxins that target human glycoprotein nmb
GB0914691D0 (en) 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
MX359551B (es) * 2009-11-24 2018-10-02 Medimmune Ltd Agentes de union diana contra b7-h1.
PT2785375T (pt) * 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
BR112014029883B1 (pt) * 2012-05-31 2023-10-24 Sorrento Therapeutics Inc. Anticorpo recombinante anti-pd-l1 e uso de um anticorpo recombinante anti-pd-l1
CN107892719B (zh) * 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EP3110445A4 (en) * 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
IL252295B2 (en) 2014-12-19 2023-10-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of using them
CN114702586A (zh) * 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
RU2767357C2 (ru) * 2016-06-14 2022-03-17 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
CN109641960A (zh) * 2016-06-29 2019-04-16 检查点治疗公司 Pd-l1特异性抗体及使用其的方法
MX2019002728A (es) * 2016-09-09 2019-08-16 Tg Therapeutics Inc Combinacion de un anticuerpo anti-cd20, inhibidor de quinasa pi3-delta, y anticuerpo anti-pd-1 o anti-pd-l1 para el tratamiento hematologico de los canceres.

Also Published As

Publication number Publication date
CA3027204A1 (en) 2018-01-04
AU2017290709B2 (en) 2024-08-01
AU2017290709A1 (en) 2019-01-24
MX2018016183A (es) 2019-06-10
RU2019102009A (ru) 2020-07-28
EP3478723A2 (en) 2019-05-08
EP3478723A4 (en) 2020-07-29
US10590199B2 (en) 2020-03-17
KR102422411B1 (ko) 2022-07-18
SG11201810927QA (en) 2019-01-30
KR20190028716A (ko) 2019-03-19
KR20220004763A (ko) 2022-01-11
US11834505B2 (en) 2023-12-05
IL276515A (en) 2020-09-30
JP2019532013A (ja) 2019-11-07
WO2018005682A3 (en) 2018-02-08
CN109641960A (zh) 2019-04-16
SG10202100100UA (en) 2021-02-25
JP7520072B2 (ja) 2024-07-22
IL263611A (en) 2019-01-31
US20240150468A1 (en) 2024-05-09
WO2018005682A2 (en) 2018-01-04
US20200277380A1 (en) 2020-09-03
RU2019102009A3 (pt) 2020-12-14
IL263611B (en) 2020-08-31
JP2022120008A (ja) 2022-08-17
US20180002424A1 (en) 2018-01-04
RU2749109C2 (ru) 2021-06-04
JP7148414B2 (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
BR112018076684A2 (pt) anticorpos pd-l1 específicos e métodos de uso dos mesmos
PH12019500270A1 (en) Combination therapy for cancer
CL2019000643A1 (es) Anticuerpos de unión a cd3.
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
CY1124408T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
BR112018076767A2 (pt) anticorpos de ligação a cd3
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
BR112018067522A2 (pt) anticorpos específicos para receptor de poliovírus humano (pvr)
BR112017002342A2 (pt) novos anticorpos e usos dos mesmos
BR112019000436A2 (pt) anticorpos anti-pd-1, método de produção e método de uso dos mesmos
GEP20207166B (en) Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
WO2018031490A3 (en) Anti-ox40 binding proteins
PE20210186A1 (es) Anticuerpos anti-sortilina y metodos para su uso
EA202091539A1 (ru) Комбинированная терапия против злокачественной опухоли антагонистом iap и молекулой против pd-1
BR112020015498A8 (pt) Anticorpos anti-pd-1
BR112017021484A2 (pt) anticorpos de direcionamento à proteína morfogenética óssea 9 (bmp9) e métodos para os mesmos
BR112019002039A2 (pt) anticorpos anti-o2 e uso dos mesmos
BR112016024214A2 (pt) anticorpos antigênicos anti-tf humanizados
BR112021008582A8 (pt) Regime de dosagem de anticorpo anti-tigit para tratamento de câncer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]